What is Zacks Research’s Estimate for BAX Q1 Earnings?

Baxter International Inc. (NYSE:BAX) – Equities researchers at Zacks Research reduced their Q1 2025 EPS estimates for shares of Baxter International in a research report issued on Thursday, March 13th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will earn $0.49 per share for the quarter, down from their prior forecast of $0.50. The consensus estimate for Baxter International’s current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International’s Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.66 EPS, Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.73 EPS, FY2026 earnings at $2.63 EPS and FY2027 earnings at $2.82 EPS.

BAX has been the subject of a number of other reports. Barclays increased their target price on shares of Baxter International from $39.00 to $41.00 and gave the company an “overweight” rating in a research report on Monday, March 10th. JPMorgan Chase & Co. reduced their target price on shares of Baxter International from $38.00 to $36.00 and set a “neutral” rating for the company in a research report on Friday, February 21st. Argus upgraded shares of Baxter International from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. The Goldman Sachs Group assumed coverage on shares of Baxter International in a research note on Wednesday, February 26th. They set a “buy” rating and a $42.00 price target on the stock. Finally, Citigroup dropped their price target on shares of Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $38.56.

Baxter International Stock Up 0.3 %

Baxter International stock opened at $34.64 on Monday. Baxter International has a twelve month low of $28.34 and a twelve month high of $43.99. The firm has a 50 day moving average price of $32.46 and a 200-day moving average price of $33.95. The company has a market capitalization of $17.72 billion, a P/E ratio of -27.06, a P/E/G ratio of 0.93 and a beta of 0.60. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.06. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The firm had revenue of $2.75 billion during the quarter, compared to the consensus estimate of $2.67 billion.

Baxter International Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Friday, February 28th will be paid a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 1.96%. The ex-dividend date of this dividend is Friday, February 28th. Baxter International’s dividend payout ratio is presently -53.13%.

Institutional Trading of Baxter International

Institutional investors and hedge funds have recently bought and sold shares of the company. CoreFirst Bank & Trust purchased a new stake in Baxter International in the 4th quarter worth approximately $26,000. Riverview Trust Co raised its position in shares of Baxter International by 5,488.2% during the 4th quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 933 shares in the last quarter. LRI Investments LLC raised its position in shares of Baxter International by 60.8% during the 3rd quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 590 shares in the last quarter. CKW Financial Group raised its position in shares of Baxter International by 100.0% during the 3rd quarter. CKW Financial Group now owns 2,200 shares of the medical instruments supplier’s stock valued at $81,000 after buying an additional 1,100 shares in the last quarter. Finally, Bruce G. Allen Investments LLC raised its position in shares of Baxter International by 247.3% during the 4th quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier’s stock valued at $76,000 after buying an additional 1,867 shares in the last quarter. 90.19% of the stock is currently owned by hedge funds and other institutional investors.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.